Moleculin Biotech Stock Soars 18.69% on Positive Annamycin Trial Results

Moleculin Biotech's stock surged 18.69% in pre-market trading on June 5, 2025, driven by the release of positive topline efficacy results from its U.S. Phase 1B/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma lung.

Moleculin Biotech reported that the positive topline results from the trial of Annamycin were incredibly encouraging. The trial demonstrated a significant impact on median overall survival, particularly among patients with soft tissue sarcoma lung.

On June 4, 2025, Moleculin Biotech announced the completion of its U.S. Phase 1B/2 clinical trial for Annamycin, highlighting the positive topline efficacy results. This news has sparked optimism among investors, leading to a notable increase in the company's stock price.

The positive results from the clinical trial have reinforced the potential of Annamycin as a treatment option for soft tissue sarcoma lung, which has historically been challenging to treat. The company's ongoing efforts in clinical research and development are expected to continue driving its stock performance.